No spam - just the good stuff

Subscribe to our newsletter

News

Investment

Crucible Therapeutics spins out with £5m for neurodegenerative disease gene therapies

Vivante gobbles up $31m for digestive health tech

Researchers land $3.2m to study impact of microbiome disruption on Alzheimer’s

Researchers at the University of Alabama to investigate the effects of microbiome disruption on Alzheimer’s disease progression.

‘We are information machines – and it’s time to renew the code.’

Venture firm age1 launches with $35 million to extend healthy lifespan

Broken String snags $15 million to make cell and gene therapy safer

NMN Bio and Aster Pharmacy unite to bring antiaging supplements to UAE market

Leveraging the past to illuminate longevity for the future

Carenostics raises $5m for AI-powered chronic disease diagnosis

Sonera exits stealth with $11m for neural sensing chip technology

Bold bags $17m to expand healthy aging platform for Medicare members

Rejuveron lands $75m to advance healthy aging portfolio; expands focus in Middle East

ProMIS raises $20.4m PIPE round for neurodegenerative disease therapeutics

Rejuvenation Technologies exits stealth with $10.6m for age-reversing mRNA therapeutics

Beta Bionics raises $100m to advance diabetes tech

Meet the founder: Garri Zmudze

Elastin Biosciences announces breakthrough discovery in elastin restoration

Young blood rising: new plasma therapy moves closer to the clinic

AgeX to merge with Serina Therapeutics

Thorne to be acquired by L Catterton for $680 million in cash

Neurowyzr bags additional $2.1m to advance brain health tech

Neuronascent lands NIA grant to advance Alzheimer’s treatment to Phase 2 clinical trials

AI drug discovery company raises $200m Series B

Viome lands $86.5m and US retail deal for gut health test

Meet the founder: Carolina Reis Oliveira

Stealth Bio lands grant from Michael J Fox Foundation to advance Parkinson’s therapy

KetoSwiss raises $4.8m to boost brain energetics via therapeutic ketosis

Neuralink raises $280 million following clinical trial go-ahead

GERO and FOXO Technologies embark on joint initiative on AI and epigenetic data

Amber Bio raises $26 million for gene editing technology

Swiss longevity company Epiterna exits stealth to tackle aging

Publicly traded longevity companies announce new finance

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.